SG11201405621UA - Methods of treating cancer using aurora kinase inhibitors - Google Patents
Methods of treating cancer using aurora kinase inhibitorsInfo
- Publication number
- SG11201405621UA SG11201405621UA SG11201405621UA SG11201405621UA SG11201405621UA SG 11201405621U A SG11201405621U A SG 11201405621UA SG 11201405621U A SG11201405621U A SG 11201405621UA SG 11201405621U A SG11201405621U A SG 11201405621UA SG 11201405621U A SG11201405621U A SG 11201405621UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- treating cancer
- kinase inhibitors
- aurora kinase
- aurora
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613258P | 2012-03-20 | 2012-03-20 | |
| PCT/US2013/032962 WO2013142491A1 (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201405621UA true SG11201405621UA (en) | 2014-10-30 |
Family
ID=48048255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607741RA SG10201607741RA (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
| SG11201405621UA SG11201405621UA (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607741RA SG10201607741RA (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20130303519A1 (en) |
| EP (1) | EP2827855B1 (en) |
| JP (1) | JP6373252B2 (en) |
| KR (1) | KR102128866B1 (en) |
| CN (1) | CN104271129A (en) |
| AU (1) | AU2013235275B2 (en) |
| CA (1) | CA2868024A1 (en) |
| EA (1) | EA036434B1 (en) |
| ES (1) | ES2746946T3 (en) |
| GE (1) | GEP20186900B (en) |
| HK (1) | HK1206253A1 (en) |
| IL (1) | IL234686B (en) |
| IN (1) | IN2014DN08477A (en) |
| JO (1) | JO3630B1 (en) |
| MA (1) | MA37438A1 (en) |
| MX (1) | MX358411B (en) |
| MY (1) | MY175225A (en) |
| NZ (1) | NZ700744A (en) |
| PH (1) | PH12014502109A1 (en) |
| SG (2) | SG10201607741RA (en) |
| TN (1) | TN2014000387A1 (en) |
| TW (1) | TWI649082B (en) |
| UA (1) | UA117455C2 (en) |
| WO (1) | WO2013142491A1 (en) |
| ZA (1) | ZA201407551B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CA2972076A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| JP6786530B2 (en) * | 2015-07-02 | 2020-11-18 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Biomarker of response to selective inhibitors of Aurora A kinase |
| CN114681455A (en) * | 2018-08-17 | 2022-07-01 | 深圳微芯生物科技股份有限公司 | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical application thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| IL59316A (en) | 1979-02-07 | 1983-07-31 | Sparamedica Ag | Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| CN1084747C (en) | 1996-03-08 | 2002-05-15 | 曾尼卡有限公司 | Azolobenzazepine derivs. as neurologically active agents |
| JP2001507349A (en) | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| CN1155599C (en) | 1997-09-29 | 2004-06-30 | 明治制果株式会社 | Tricyclic triazolobenzazepine derivatives, process for producing same, and antiallergic |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| KR100876069B1 (en) | 2000-09-15 | 2008-12-26 | 버텍스 파마슈티칼스 인코포레이티드 | Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same |
| MXPA03005610A (en) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors. |
| SI20848A (en) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Pharmaceutical formulation containing atorvastatin calcium |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| DE10135457A1 (en) | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optical sensor device for use in automobile positioned behind transparent panel with lamella elements between latter and optical transmitter-receiver |
| MXPA04001252A (en) | 2001-08-09 | 2004-05-27 | Actelion Pharmaceuticals Ltd | Novel benzo-fused heterocycles as endothelin antagonisits. |
| CN1897950A (en) | 2003-10-14 | 2007-01-17 | 惠氏公司 | Fused-aryl and heteroaryl derivatives and methods of their use |
| CA2554271A1 (en) | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| JP4467616B2 (en) | 2004-05-14 | 2010-05-26 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Compounds and methods for blocking mitotic progression by inhibition of Aurora kinase |
| KR20070086188A (en) | 2004-11-17 | 2007-08-27 | 미카나 테라퓨틱스, 인크. | Kinase inhibitors |
| WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| CN101389324A (en) | 2005-12-23 | 2009-03-18 | 史密丝克莱恩比彻姆公司 | Azaindole inhibitors of aurora kinases |
| EP1973532A1 (en) | 2006-01-16 | 2008-10-01 | Jubilant Organosys Limited | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
| WO2008020314A2 (en) | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
| DE102006012301A1 (en) | 2006-03-15 | 2007-09-20 | Cemag-Anlagenbau-Dessau Gmbh | Production of cement clinker |
| US7718648B2 (en) | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CA2668267A1 (en) | 2006-10-31 | 2008-05-08 | Achillion Pharmaceuticals, Inc. | Elvucitabine pharmaceutical compositions |
| CL2007003244A1 (en) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER. |
| AR065802A1 (en) | 2007-03-22 | 2009-07-01 | Schering Corp | FORMULATIONS OF TABLETS CONTAINING SALTS OF 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) FENIL) -ETOXI) - METHYL) -8- PHENYL -1, 7- DIAZA- SPIRO [4,5] DECAN - 2- ONA AND TABLETS PREPARED FROM THESE |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
| US20110212157A1 (en) | 2008-06-26 | 2011-09-01 | Anterios, Inc. | Dermal delivery |
| JO3635B1 (en) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | Solid pharmaceutical compositions and processes for their production |
| JO3434B1 (en) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
| JP2013520424A (en) * | 2010-02-19 | 2013-06-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Sodium 4-{[9-chloro-7- (2-fluoro-6-methoxyphenyl) -5H-pyrimido [5,4-d] [2] benzoazepin-2-yl] amino} -2-methoxybenzoate Crystal form |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
-
2013
- 2013-03-14 US US13/804,570 patent/US20130303519A1/en not_active Abandoned
- 2013-03-18 JO JOP/2013/0075A patent/JO3630B1/en active
- 2013-03-19 UA UAA201411324A patent/UA117455C2/en unknown
- 2013-03-19 MX MX2014011324A patent/MX358411B/en active IP Right Grant
- 2013-03-19 JP JP2015501852A patent/JP6373252B2/en active Active
- 2013-03-19 AU AU2013235275A patent/AU2013235275B2/en active Active
- 2013-03-19 WO PCT/US2013/032962 patent/WO2013142491A1/en active Application Filing
- 2013-03-19 ES ES13714455T patent/ES2746946T3/en active Active
- 2013-03-19 EP EP13714455.6A patent/EP2827855B1/en active Active
- 2013-03-19 SG SG10201607741RA patent/SG10201607741RA/en unknown
- 2013-03-19 SG SG11201405621UA patent/SG11201405621UA/en unknown
- 2013-03-19 CA CA2868024A patent/CA2868024A1/en not_active Abandoned
- 2013-03-19 KR KR1020147028776A patent/KR102128866B1/en active IP Right Grant
- 2013-03-19 IN IN8477DEN2014 patent/IN2014DN08477A/en unknown
- 2013-03-19 MY MYPI2014702635A patent/MY175225A/en unknown
- 2013-03-19 MA MA37438A patent/MA37438A1/en unknown
- 2013-03-19 CN CN201380015806.1A patent/CN104271129A/en active Pending
- 2013-03-19 GE GEAP201313599A patent/GEP20186900B/en unknown
- 2013-03-19 EA EA201491727A patent/EA036434B1/en not_active IP Right Cessation
- 2013-03-19 NZ NZ700744A patent/NZ700744A/en not_active IP Right Cessation
- 2013-03-20 TW TW102109912A patent/TWI649082B/en active
-
2014
- 2014-09-15 TN TNP2014000387A patent/TN2014000387A1/en unknown
- 2014-09-16 IL IL234686A patent/IL234686B/en active IP Right Grant
- 2014-09-22 PH PH12014502109A patent/PH12014502109A1/en unknown
- 2014-10-17 ZA ZA2014/07551A patent/ZA201407551B/en unknown
-
2015
- 2015-07-17 HK HK15106841.1A patent/HK1206253A1/en unknown
- 2015-09-03 US US14/844,270 patent/US10213436B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288181A (en) | Methods of treating cancer | |
| IL274318A (en) | Treatment of cancer with tor kinase inhibitors | |
| HK1243919A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| HK1202247A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201750A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201753A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1206253A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| HK1223832A1 (en) | Kinase inhibitors for the treatment of cancer | |
| EP2897607A4 (en) | Inhibitors of beta-hydrolase for treatment of cancer | |
| ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors |